Duchenne muscular dystrophy is an X-linked disease caused by the absence of functional
dystrophin in the muscle cells. Major advances have led to the development of gene …

Sarcopenia is a progressive syndrome that results in a decline in skeletal muscle mass and
strength. This affects patients' quality of life and increases the risk of falls and fractures …

Myostatin inhibition therapy has held much promise for the treatment of muscle wasting
disorders. This is particularly true for the fatal myopathy, Duchenne Muscular Dystrophy …

Oligonucleotides have shifted drug discovery into a new paradigm due to their ability to
silence the genes and inhibit protein translation. Importantly, they can drug the un-druggable …

Muscular dystrophies (MDs) are heterogeneous diseases, characterized by primary wasting
of skeletal muscle, which in severe cases, such as Duchenne Muscular Dystrophy (DMD) …

The use of peptides as drugs has progressed over time and continues to evolve as treatment
paradigms change and new drugs are developed. Myostatin (MSTN) inhibition therapy has …

Duchenne muscular dystrophy (DMD) is an X-linked condition caused by a deficiency of
functional dystrophin protein. Patients experience progressive muscle weakness …

We evaluated whether whole-body dual-energy X-ray absorptiometry (DXA) measures of
lean body mass can be used as biomarkers for disease progression and treatment effects in …

Background: Hepatic sarcopenia is one of many complications associated with chronic liver
disease (CLD) and has a high mortality rate; however, the liver-muscle axis is not fully …

Current research findings in humans and other mammalian and non-mammalian species
support the potent regulatory role of myostatin in the morphology and function of muscle as …